Moneycontrol

Moneycontrol PRO

HomeNews

Gbr 500

Jump to

Although robust nos, analysts cautious of Glenmark

Glenmark Pharma reported stronger-than-expected numbers on all parameters as its consolidated net profit grew by 4.6 times year-on-year to Rs 213 crore in the third quarter of financial year 2012-13.
Glenmark's R&D gamble

With Indian pharma companies willing to cash out, is Glenn Saldanha India’s best bet for a home-grown drug?

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347